button bars forest bayes pooled summary circles
 
DCR

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus Ipilimumab (10 mg/kg)
nivolumab alone vs. Ipilimumab (10 mg/kg) 1 -
versus placebo
nivolumab alone vs. placebo 1 -
pembrolizumab alone vs. placebo 1 -

mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive

versus placebo
pembrolizumab alone vs. placebo 1 -

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab alone vs. ipilimumab alone 1 -
versus ipilimumab followed by nivolumab
nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab 1 -

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 -

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus dacarbazine
nivolumab alone vs. dacarbazine 1 -
versus pembrolizumab alone
atezolizumab plus cometinib vs. pembrolizumab alone 1 certainty unassessable-8%

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus ipilimumab alone
pembrolizumab (10mg/kg) vs. ipilimumab alone 1 -
pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone 1 -
versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC) 1 -
pembrolizumab (10mg/kg) vs. Standard of Care (SoC) 1 -
pembrolizumab (2mg/kg) vs. Standard of Care (SoC) 1 -

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 -

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons